Sangamo Therapeutics has patented methods to develop AAV capsids with specific characteristics for delivering genome engineering and gene therapy molecules. The patent involves AAV capsid proteins with defined amino acid sequences, enhancing treatment options for various conditions. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of May 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Developing aav capsids for gene therapy delivery
A recently granted patent (Publication Number: US11981967B2) discloses an invention related to AAV capsid proteins. The patent claims cover various aspects of AAV capsid proteins, including specific amino acid sequences and their insertion into different serotypes. For instance, the patent claims describe AAV capsid proteins comprising at least 4 contiguous amino acids from specific sequences listed in SEQ ID NO: 1-32 or SEQ ID NO: 68-110. Furthermore, the patent specifies the inclusion of these amino acid sequences in various AAV serotypes such as AAV1, AAV2, AAV3B, AAV5, AAV6, AAV8, AAV9, AAV3, AAV4, AAV7, AAV11, AAVrh10, AAVrh39, or AAVrh74.
Moreover, the patent details the insertion of specific amino acid sequences, like SEQ ID NO: 90, into different serotypes of AAV capsid proteins at precise amino acid positions. These positions range from 266 to 591, highlighting the specificity and versatility of the disclosed invention. By providing a detailed description of the amino acid sequences, their insertion points, and the targeted serotypes, the patent aims to protect the novel AAV capsid protein compositions and their potential applications in various biotechnological and therapeutic fields.
To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
